The Forum for Innovative Regenerative Medicine (FIRM)

Ver.1.0

Info Sheet for Technical description

No. 0006

Organization

* Mandatoty fields

Name of Organization*	JUNTEN BIO Co., Ltd.	
Address, City, States, Zip, Country*	20F Otemachi Nomura Bldg., 2-1-1 Otemachi, Chiyoda-ku, Tokyo 100-0004 JAPAN	
URL	https://juntenbio.co.jp/en/	
Brief Descriptions of Organization* (Approx. 100 words)	JUNTEN BIO, established in 2018 with property license from Juntendo University, is a clinical-stage biotech company which is developing "Cell Therapy" that induces unresponsiveness of the immune system to a specific antigen. Our approach is to induce T cells ex vivo to suppress only the immune response to the target antigen without any gene transfer, and then return the cells to the body to suppress the specific immune response. Our initial target is the development of cell therapy for complete elimination of immunosuppressant for "transplant rejection". PhaseI/II crinical trials are being conducted at the moment in Japan.	
Contact address	Name*	Shusaku Sakata
	Department* / Position	Business Developemnt / Executive Officer, General Manager
	E-mail* / TEL	sakata@juntenbio.co.jp

What kind of technology do you want to offer? *

- ☑ **A.** Clinical Development Pipelines → Please see **Sheet【A】**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Servicies etc. → Please see **Sheet【B】**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet【C】**

  * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☑ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☐ Yes
- ☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☑ Series B
- ☐ Series C
- ☐ Series D or further advenced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☑ Yes	
☐ No	

Filled in by*	Shusaku Sakata, Executive Officer, General Manager of Business Development Dept.
Date*	2023/9/20

Ver.1.0

Sheet【A】 Clinical Development Pipelines

Info Sheet for Technical overview

No. 0006

* Mandatoty fields

Title*

Antigen specific iTs (induced T cells with suppressing function) cell therapy

Development Phase*

☐	Basic Research	☐	Drug Discovery	☐	Pre-Clinical
☑	Clinical Trial (Phase I)	☑	Clinical Trial (Phase II)	☐	Clinical Trial (Phase III)
☐	Review	☐	Others		

Diesease Area*

☐	Cancer	☐	Central nervous system	☐	Ophthalmology
☐	Musculoskeletal	☐	Endocrine / Metabolism	☐	Cardiovascular
☐	Urogenital	☐	Digestive organ	☐	Blood
☐	Infection	☐	Dermatology	☑	Immunity
☐	Otolaryngology	☐	Respiratory	☑	Others

Description*

Patients with organ transplants must take immunosuppressants continuously for the rest of their lives to control rejection. Based on our clinical studies in which seven liver transplant patients out of ten have been achieved transplant tolerance over 10 years by our donor antigen specific iTs (induced T cells with suppressing function) cell therapy. We have been conducting Phase I/II Clinical Trials for this iTs cell therapy, JB-101, with step-wise weaning and withdrawal of immunosuppressant after transplant. Scientific platform of this iTs could be also adopted to autoimmune diseases. A breakthrough technology in the area of Cell Therapy/Regenerative Medicine.

Filled in by*	Shusaku Sakata
Date*	2023/9/8